Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

End-of-day quote. End-of-day quote  - 02/12
21.5 CHF   -0.46%
01/27 NEWRON PHARMACE : to Present at the 18th Annual BIO CEO & Investor C..
01/12 NEWRON PHARMACE : Zambon Launches Xadago® (Safinamide) in Switzerlan..
01/12 Zambon launches Xadago® (Safinamide) in Switzerland for patients ..
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA engages in the research and development of therapies for patients with diseases of the Central Nervous System and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20132014Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs3.95100%1.58100% -150.52%
Sales per Regions
20132014Delta
CHF (in Million)%CHF (in Million)%
Global3.95100%1.58100% -150.52%
Managers
NameAgeSinceTitle
Stefan Weber512005Chief Executive Officer, MD, Director & IR Contact
Ulrich Köstlin, PhD642013Non-Executive Chairman
Roberto Galli-2002VP-Finance & Investor Relations Contact
Ravi Anand, MD592005Chief Medical Officer
Patrick J. Langlois, PhD712008Independent Director
Hanns Moehler, MD-2008Non-Executive Director
Roberto Consonni-2012Non-Executive Director
Robert Leslie Holland MD, PhD612013Non-Executive Director
Bo Jesper Hansen MD, PhD582013Non-Executive Director
Joseph Donald deBethizy, PhD65-Member-Supervisory Board
Shareholders
NameEquities%
Investor AB 1,772,817 12.5%
Gefim SpA 1,311,957 9.23%
JPMorgan Asset Management (UK) Ltd. 409,571 2.88%
Swisscanto Fondsleitung AG 343,223 2.41%
UBS AG (Investment Management) 228,945 1.61%
Polar Capital LLP 158,148 1.11%
Aviva Investors Global Services Ltd. 119,989 0.84%
Credit Suisse AG 90,269 0.63%
Michel & Cortesi Asset Management AG 48,218 0.34%
Deka Investment GmbH 32,500 0.23%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
GILEAD SCIENCES, ..
AMGEN, INC.
CELGENE CORPORATI..
REGENERON PHARMAC..
VERTEX PHARMACEUT..
SHANGHAI RAAS BLO..
-
ACTELION LTD
GENMAB A/S
MEDIVATION INC
TONGHUA DONGBAO P..
HUALAN BIOLOGICAL..
NEUROCRINE BIOSCI..
JUNO THERAPEUTICS..
INTERCEPT PHARMAC..
3SBIO INC
-
CHINA BIOLOGIC PR..
BEIJING SL PHARMA..
ZHONGYUAN UNION C..
ULTRAGENYX PHARMA..
-
KITE PHARMA INC
Sector Biotechnology & Medical Research
Newron Pharmaceuticals SpA : Connections
DFC Langlois
AGY Therapeutics, Inc.
Orphazyme ApS
Swiss National Center of Neuroscience Research
Karolinska Development AB (Private Equity)
Swiss Federal Institute of Technology
CMC Contrast AB
European Academy of Sciences
White City Consulting ApS
Swiss Academy of Medical Sciences
Constantia Flexibles Group GmbH
PJL Consulting
European School of Management & Technology GmbH
Constantia Flexibles AG
Universitätsklinikum Würzburg
Italia Assistenza SpA
MipSalus ApS
Oxford Gene Technology IP Ltd.
Roche Innovation Center Copenhagen A/S
Early Clinical Development Consulting Ltd.
Z-Cube SRL
Axxam SpA
NOXXON Pharma AG
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
© 2016 People , Fundamentals and Ownership